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Stress-induced hyperglycemia in critically ill patients negatively affects their 
recovery. Providers have struggled to balance the treatment of hyperglycemia with 
aggressive insulin therapy with the risk of hypoglycemia as an adverse effect. Both 
immobilization and continuous enteral nutrition are common in a critical care setting and 
have implications as contributors for further hyperglycemia due to decreased peripheral 
glucose uptake and worsening insulin resistance. We propose to determine if an 
aggressive early mobilization protocol and nutrition protocol in the form of bolus feeds 
will decrease the amount of insulin units needed to treat hyperglycemia in critically ill 
patients. To do so, patients over 18 years old will be randomized to one of four 
intervention groups receiving either standard of care and/or intervention nutrition and 
mobilization protocol, in a medical intensive care unit at two campuses of an academic 
institution. The results could change the management of hyperglycemia in critically ill 
patients, limiting the amount of insulin units required and lowering the risks of 
hypoglycemia.  
1 
Chapter 1 – Introduction 
Background  
Stress Hyperglycemia 
In critical illness, patients often become hyperglycemic (defined as a fasting blood 
glucose >126mg/dL or a random blood glucose >200mg/dL1). Hyperglycemia is an 
evolutionary adaptive response to stress by the hypothalamic-pituitary-adrenal axis, 
sympathoadrenal system and proinflammatory cytokines to synergistically increase 
available glucose2. A complex combination of endogenous and exogenous factors 
contribute to hyperglycemia such as increased insulin resistance, decreased insulin 
production, increased glucose levels (secondary to failure to suppress gluconeogenesis as 
well as administration of nutritional support with excess glucose), and/or increased 
counter-regulatory hormones controlling the whole process3.  
While partially adaptive, this stress hyperglycemia has downstream consequences 
for the body and impacts recovery from critical illness. Hyperglycemia can lead to fluid 








Figure 1. Mechanisms of Stress-Induced Hyperglycemia 4 
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effects including mitochondrial injury, neutrophil dysfunction, and endothelial 
dysfunction5. On a molecular level, it can lead to oxidant injury, protein glycation, and 
complement inhibition. Taken together, in a wide variety of disease states, uncontrolled 
hyperglycemia has been associated with increased mortality as well as morbidity from 
complications such as infections6.  
Intensive Insulin Therapy  
Given the known physiologic consequences of over-exuberant excursions in 
blood glucose levels, researchers and providers have attempted to address this problem of 
hyperglycemia and minimize its effects on patient recovery and mortality. Early studies 
looked at aggressive and early implementation of intensive insulin therapy (IIT) to 
maintain a target blood glucose of 80-110mg/dL. A landmark study performed in a 
surgical intensive care unit (SICU) in Leuven, Belgium comparing insulin treatment of 
hyperglycemia with IIT versus a more conservative target blood glucose of <180mg/dL 
showed a statistically significant and successful reduction in morbidity and mortality in 
the IIT group7. Another study by the same research team looked at the effects of IIT in 
the medical intensive care unit (MICU) and again showed an overall reduction in 
morbidity, but a reduction in mortality was only seen among patients staying in the 
intensive care unit (ICU) for more than 3 days8. These studies helped solidify IIT’s place 
in standard clinical practice in the ICU which was quickly endorsed by multiple 
professional societies. 
However, in subsequent years, further studies have had conflicting results and led 
to equipoise, leaving providers less certain about the benefits of aggressive 
hyperglycemia management among critically ill patients9-12. For example, two studies by 
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Prieser et al. and Brunkhorst et al. demonstrated an increased risk for serious adverse 
effects related to hypoglycemia and no significant difference in mortality among patients 
receiving IIT compared to a more modest blood glucose target of 140-180 mg/dL10,11. In 
the large randomized trial, Normoglycemia in Intensive Care Evaluation and Surviving 
Using Glucose Algorithm Regulation (NICE-SUGAR), researchers found that IIT with a 
blood glucose target of 81-108mg/dL compared to a moderate glucose target of 140-
180mg/dL actually increased mortality among critically ill patients and led to 
significantly more hypoglycemic episodes (defined as <40mg/dL)13.   
While some have questioned the magnitude of harm related to hypoglycemic 
events occurring in a closely monitored ICU setting where appropriate treatment is 
promptly administered, the concern regarding severe hypoglycemia rates seems 
warranted. Severe hypoglycemia is independently associated with increased mortality in 
several studies14. In the ICU, both severe hypoglycemia and multiple hypoglycemic 
events within the same patient have been associated with increased 90 day mortality15.  
Given that attempts to control blood glucose values with insulin always come with some 
price in terms of increasing hypoglycemia rates no matter how carefully a glucose 
management protocol is followed, the ideal target blood glucose range (balancing the 
hyper- and hypoglycemia associated risks) as well as novel (non-insulin dependent) 
interventions that ameliorate the insulin resistant state during critical illness have been 
under discussion. Leveraging early mobilization as well as optimizing nutrition delivery 
may be examples of non-insulin dependent means to improve glucose control in the ICU, 
but there are few studies which have specifically examined this.  
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Mobilization in the ICU – Benefits and Its Impact on Glycemic Control  
In recent years, immobilization and lack of aggressive physical therapy (PT) have 
also been associated with morbidity in the ICU. As a corollary, implementation of an ICU 
mobilization protocol has been associated with improved patient outcomes. While 
improvement in patient outcomes have been attributed to a number of factors, such as 
fewer delirium days and sedation holidays16, one of the added benefits of ICU 
mobilization may be improved glycemic control. Significant insulin resistance has been 
associated with limitations on physical activity, such as seen in a bedbound ICU patient17. 
Immobility and ICU-acquired weakness have been shown to increase insulin resistance 
and reduce peripheral glucose uptake18. 
During physical activity, the contracting muscle increases rate of glucose uptake, 
and these benefits can last for hours after exercise19. A secondary analysis of a previous 
study showed that early mobilization in ICU patients was associated with decreased need 
for insulin to maintain euglycemia (0.07units/kg/day versus 0.2 units/kg/day)20. Other 
associated benefits of early mobilization include improved cognitive function16, improved 
functional exercise capacity, and improved self-perceived functional status at discharge21. 
Early mobilization has been incorporated into many critical care settings, but due 
to limited physical therapists and occupational therapists, time constraints, inadequate 
staff training, and lack of staff support22, outside of the research realm, it has been a 
challenge to implement an early mobilization protocol. There have also been lingering 
concerns regarding safety, despite evidence supporting safe mobilization of even 
mechanically ventilated critically ill adults23. 
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Nutritional Support During Critical Illness and Its Metabolic Consequence  
Another contributing factor to hyperglycemia in ICU patients is nutrition. While it 
seems intuitive that enteral nutritional support would have a positive impact during 
critical illness, how best to deliver it is less well studied. Prior studies have already 
shown that enteral nutrition (EN) can preserve intestinal microbial diversity24 and 
maintain gastrointestinal (GI) tract mucosal integrity25 compared to parenteral nutrition 
(PN). However, very few studies have examined when and how to deliver that nutritional 
content, and without much evidence to support the practice, continuous provision (24 
hours a day) of EN has become the norm. This practice, however, may have unintended 
consequences. Continuous uninterrupted 24 hour infusion of ‘food’ does not mimic the 
natural progression of eating a meal and the subsequent release of digestive enzymes and 
hormones. After meal consumption for example, serum glucose levels increase, leading 
to a release of insulin as well as the down-regulation of glucagon. The enterohormonal 
feedback loop is tightly regulated and highly preserved across species. After a meal, GI 
hormones rapidly rise and then return to basal levels. This cycle of rise and fall of 
hormone levels is interrupted by continuous tube feeding1. When nutrition is constantly 
running through the digestive tract, insulin is constantly being released basally and the 
post-prandial surge is lost. There may even be a downregulation of insulin receptors over 
time. Downstream, this may be promoting an insulin resistant state and contributing to 
hyperglycemia. In an average day outside of the hospital, a patient is not eating 
continuously all day, but would likely consume about three meals a day and a few snacks 
in between. If it were possible to mimic these meal times with boluses of food instead of 
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a continuous infusion, patients may be able to maintain a more physiologic hormonal 
state. 
Statement of the Problem  
Currently, providers are attempting to balance the benefit of hyperglycemia 
treatment via exogenous insulin administration with the risk of hypoglycemia by 
adopting a less stringent glucose goal. The most recent recommendations from the 
American College of Physicians suggest a target blood glucose level between 140-
200mg/dL among SICU/MICU patients26. While immobilization and nutrition are 
contributors to hyperglycemia in the ICU, it is unknown how these factors may be 
intervened upon as adjunctive therapy beyond traditional insulin administration in an 
effort to more holistically manage glucose control during critical illness. Such non-insulin 
dependent management tools may have the additional benefit of less ‘cost’ in terms of 
severe hypoglycemia.  
Goals and Objectives 
 The goal of this study is to examine whether implementation of a bundled 
supportive care regimen which includes a) an early and aggressive ICU mobilization 
program and b) intermittent bolus EN, could be a safe and feasible adjunct therapies for 
hyperglycemia in the critically ill patient using a 2 x 2 factorial design. Glycemic control 
metrics (such as average glucose levels, insulin requirements, peak and nadir glucose 
levels) will be examined among 4 groups of patients: (1) those who receive standard 
mobilization and continuous (24 hours a day) EN; (2) those who received standard 
mobilization and intermittent bolus (meals and snacks) EN; (3) those who receive 
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aggressive ICU mobilization and continuous (24 hours a day) EN; and (4) those who 
receive aggressive ICU mobilization and intermittent bolus (meals and snacks) EN.  
Hypothesis  
We hypothesize that an aggressive early mobilization protocol paired with an EN 
protocol utilizing intermittent bolus feeds will together decrease the amount of insulin 
units needed to treat hyperglycemia in critically ill patients in the ICU, compared to those 
receiving standard mobilization and continuous enteral nutrition. 
Definitions 
Hyperglycemia: fasting blood glucose >126mg/dL or a random blood glucose 
>200mg/dL 
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Chapter 2 – Review of the Literature 
Introduction 
 
 In this chapter, we will present a comprehensive literature review to summarize, 
compare and contrast, and critically evaluate previous research on this topic. This review 
of the literature between August 1980 and July 2017 was conducted using 
PubMed@Yale, OVID (Medline and Embase), Scopus, and Cochrane databases. 
Keywords used to find the necessary articles to conduct the literature review included 
those in Table 1 below. Applicable articles were limited to those written in or translated 
to English. Systematic review articles, randomized controlled trials, prospective and 
retrospective studies as well as relevant referenced articles were all used to complete the 
literature review necessary to validate this proposed study.  
Table 1. Literature Search Key Terms 
Critical Illness / Critically Ill / Intensive Care Unit / Critical Care 




Review of Empirical Studies Regarding Mobilization  
Early and aggressive mobilization has been shown to have beneficial effects on 
critically ill patients1-3. Burtin et al. performed a randomized controlled trial in a medical 
and surgical ICU at an academic institution with 90 critically ill patients1. While both the 
control and intervention groups received respiratory PT and daily standardized passive or 
active range of motions session of upper and lower limbs, the intervention group also 
received daily passive or active exercise training using a bedside ergometer for 20 
minutes starting from day 5 of the ICU stay once cardiorespiratory status was felt to be 
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sufficiently stabilized. While there was no difference with regard to quadriceps force and 
functional status between the control and intervention groups, six minute walking 
distance, isometric quadriceps force, and subjective feeling of functional well-being (per 
a validated health survey) were all significantly higher in the intervention group (p<0.05) 
at time of hospital discharge. No adverse events related to mobilization occurred in this 
study. This was one of the earlier studies that suggested benefit and feasibility of early 
exercise amongst ICU patients and informed subsequent studies. 
 In 2013, Engel et al. examined the implementation of an ICU early mobility 
quality improvement initiative from three separate institutions, which included the MICU 
at Wake Forest University (WFU), the MICU at Johns Hopkins Hospital (JHH), and the 
mixed surgical-medical ICU at University of California San Francisco Medical Center 
(UCSF)3. All three institutions found reduced ICU and hospital length of stay (LOS) as 
well as improved outcomes and saved costs. For example, at WFU there was a significant 
difference in ICU LOS between usual care (6.8 days) in comparison to the protocol group 
(5.5 days) as well as a significant difference in overall hospital LOS (14.5 days in usual 
care versus 11.2 days in protocol group). They also found a net savings of over a half a 
million dollars of total direct inpatient cost in the protocol group. JHH and UCSF had 
similar results. The program at JHH additionally found decreased rates of delirium and 
need for sedation. All three of the locations required an interprofessional team-based 
approach to plan, educate, and implement the early mobilization program including but 
not limited to physical therapists, occupational therapists, physical medicine, critical care 
providers, neurology providers, clinical and nursing staff. At a certain point in the 
implementation, UCSF found themselves in a shortage of staffing to maintain the 
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protocol. While safe, feasible, and beneficial for a wide range of critically ill patients, 
Engel’s study highlighted implementation challenges related to early mobilization which 
ranged from infrastructure resource needs to multidisciplinary stakeholder buy-in.  
We are thus left with a disconnect—while research evidence has continued to 
accumulate that early mobilization is beneficial among ICU patients, the bedside reality 
is that early mobilization is frequently not occurring to the extent that it can or should. 
Upon investigation into the current state of ICU mobilization, the Trial of Early Activity 
and Mobilization (TEAM) Study investigators found in their multi-center, prospective 
cohort study that early mobilization of mechanically ventilated patients was uncommon4. 
In 12 ICUs across Australia and New Zealand between August 2012 and March 2013, 
192 patients who were previously functionally independent and expected to be ventilated 
for greater than 48 hours were followed for 14 days or until liberated from the ventilator, 
whichever came first. Results demonstrated that 122 patients (63.5%) did not receive 
early mobilization. Of the possible 1288 patient-PT interactions while patients were 
mechanically ventilated, no early mobilization occurred in 1079 (84%) of these episodes. 
Of the 36.5% mechanically ventilated patients who did receive any active mobilization, 
less than 10% of mobilization episodes included any activities out of bed. For these 
patients, the median time from ICU admission to mobilization was 5 days and the number 
of active mobilization episodes per patient was 2. Strengths of this study include its 
prospective multicenter design as well as the fact that it took place in Australia and New 
Zealand where PT has been part of the ICU multidisciplinary team for decades4. 
However, patient follow-up was limited to 14 days which is a shortcoming given that 
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recovery from critical illness as well as the known benefits of mobilization may persist 
past 14 days.   
 With proven benefit of mobilization but real world evidence that early 
mobilization is not being implemented, what are the barriers? In their review, Dubb et al. 
examined these unique barriers to early mobility in the ICU setting which are outlined 
below in Table 25.  
Table 2. Barriers to Early Mobilization5 
Physical barriers  Patients considered too sick  
Hemodynamic instability  
Arrhythmias  
Respiratory instability  
Pain  
Poor nutrition status 
Obesity  
Baseline or new immobility or weakness 




Lack of motivation  
Anxiety  
Fatigue 
Palliative care  




Cultural barriers  Inadequate staff  
Lack of staff buy-in 
Lack of multidisciplinary culture  
Lack of patient/family knowledge 
Process related barriers Lack of planning and coordination  
Unclear expectations, roles, responsibilities  
Missed/delayed screening for ability  
Standing orders for bed-rest  




Meanwhile, additional benefits of early mobilization are being discovered. A 
secondary analysis of a previous randomized controlled trial of early PT/occupational 
therapy (OT) versus conventional therapy is one example where metabolic benefits to 
early mobilization were suggested6. In the original study, 104 MICU patients were 
randomized to receive PT/OT within 72 hours of mechanical ventilation (early) or 
standard care as ordered by primary team7. As with other studies, patients randomized to 
more intensive and early PT were shown to have improved functional independence at 
time of discharge. As part of the study, total daily insulin dose was collected during ICU 
stay and normalized to weight, and the outcome variables were measured as medians6. 
After a univariate analysis, this study established that the mobilized patients required less 
insulin (0.07 units/kg/d versus 0.2 units/kg/d, P <0.0001). This was remarkable given a 
slight and non-significant trend toward more prednisone dosage in the early mobilization 
patients. This study was unique in that it suggested that early mobilization may have 
potential utility as adjunct to insulin to improve metabolic parameters during critical 
illness. This study focused on MICU patients, eliminating the possible heterogeneity and 
varying co-morbid conditions that may otherwise exist with inclusion of surgical patients 
or patients with neurologic injury. Conversely, the focus on MICU patients limits its 
generalizability. This study took place during the era of IIT (in this study, targeting a 
blood glucose of 80-120 mg/dL) so approach to glycemic control was standardized. 
Patients in the MICU receive corticosteroids for various indications, such as for 
obstructive lung disease and relative adrenal insufficiency that can occur during severe 
septic shock. While receipt of corticosteroid was not statistically significant between 
groups, there was a trend toward more usage among patients in the early mobilization 
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arm, which may have been due to incomplete randomization. However, this could have 
biased the early mobilization group to need more (not less) insulin, and thus may in fact 
strengthen the study findings. Finally, given that this was a secondary analysis of a prior 
study, it may not have been appropriately powered to examine the metabolic impact of 
mobilization on hyperglycemia.  
Nevertheless, mechanistically, the effects of immobilization on blood glucose 
have been known. In the study by Stuart et al. from 1988, investigators aimed to quantify 
the impact of absolute bed-rest alone on the insulin regulation of glucose metabolism8. 
Six healthy men aged 21 to 28 years old were admitted and had baseline testing. On the 
sixth day of admission bed-rest was begun, and patients were confined to a water bed for 
seven days and not permitted to a deviate from a recumbent position. Glucose tolerance 
tests were performed on day 4 (during the baseline period) and day 11 (during the sixth 
day of bed-rest). Results of this study showed an increase in plasma glucagon and urinary 
free cortisol, both of which are insulin antagonists. While fasting glucose was unchanged 
by bed-rest, post-prandial challenge glucose levels tended to be elevated (p<0.05) and the 
insulin area of the glucose tolerance test was increased by 44% (p<0.01). The slight rise 
in glucose with a moderate increase in insulin secretion suggests the development of 
insulin resistance within a week of bed-rest among healthy volunteers. Given that there 
are many other factors such as increase in counter-regulatory hormones during stress 
states in the ICU, bedbound critically ill patients may thus be primed to experience 
hyperglycemia. 
Reassuringly, even short and limited exercise may help ameliorate this insulin 
resistant state. In one study, Devlin demonstrated that a single bout of exercise in non-
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insulin dependent diabetic men can increase peripheral and splanchnic insulin sensitivity 
for the subsequent 12-16 hours9.    
Review of Empirical Studies Regarding Treatment of Hyperglycemia in the ICU  
 As discussed in Chapter 1, stress hyperglycemia often occurs in critical illness 
and can have a negative impact on recovery10-13. How to best manage hyperglycemia 
during critical illness has been a topic of great controversy in the past decade.  
In 2001, Van den Berghe et al. performed a prospective randomized controlled 
trial looking at whether complete normalization of blood glucose levels with IIT reduces 
mortality and morbidity among critically ill patients14. The study included 1548 adults 
admitted to a SICU receiving mechanical ventilation. The intervention arm received IIT 
with a target blood glucose of 80-110mg/dL whereas the conventional treatment had 
insulin management with a target blood glucose of 180-200mg/dL. The study was 
originally powered to detect a 5% difference in mortality among those who remained in 
the ICU for more than five days and of 3% among all patients in the ICU. Interim 
analysis of results indicated that conventional treatment was inferior, and the study was 
stopped prior to the planned 2500 enrollment. Results demonstrated that IIT reduced 
mortality during ICU stay from 8% in the conventional group to 4.6% (p<0.04).  In 
patients who remained in the ICU for greater than five days, the mortality rate with IIT 
was 10.6% compared with 20.2% in the conventional group (p=0.005). The sickest 
patients appeared to reap the most benefit, as the largest reduction in mortality was 
observed in deaths due to multi-organ failure, particularly those with septic shock. 
Results also indicated IIT was associated with an overall reduction in hospital mortality 
by 34%, and marked improvement in clinically relevant morbidity markers such as 
17 
 
reduction of rates of bloodstream infections by 46%, acute renal failure requiring dialysis 
or hemofiltration by 41%, median number of red cell transfusions by 50%, and critical-
illness polyneuropathy by 44%. Patients in the IIT arm of the study were less likely to 
require prolonged mechanical ventilation and intensive care. One of the biggest strengths 
of this study was a novel aggressive treatment approach (using a widely available and 
cheap drug—insulin) to a known and ubiquitous problem of stress hyperglycemia during 
critical illness. Limitations of this study include that it took place exclusively in a SICU 
at one institution with a distinctive approach that emphasized the importance of glucose 
monitoring (utilizing point of care blood glucose measurements with arterial blood from 
an arterial catheter) and strict protocol adherence possibly limiting external validity and 
generalizability. Additionally, patients were supplemented with PN to meet caloric needs 
possibly increasing the insulin requirements.  
In the subsequent years since the Van den Berghe trial, there have been many 
studies with conflicting data about the use of this IIT. These studies15-18, including the 
landmark NICE-SUGAR trial19, are discussed in Chapter 1. In their systematic review, 
Ling et al. looked at 22 randomized controlled trials comparing intensive glucose control 
(<110mg/dL) to conventional glucose control in adult intensive care patients20. In this 
review, they used risk ratio (RR) as a summary measure of association with a 95% 
confidence interval. They performed a subgroup analysis on the mean blood glucose level 
achieved in the intensive group, the difference of mean blood glucose level achieved in 
the intensive and conventional control groups, the standard deviation (SD) of mean blood 
glucose (as an index of glycemic variability), the percentage of diabetic patients, the 
mean Acute Physiology and Chronic Health Evaluation (APACHE) II score, the 
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percentage of medical patients, and the mean daily insulin dose in the intensive group. 
Results of this review showed that intensive glucose control did not significantly reduce 
short term mortality, reduce rates of sepsis, or reduce new need for dialysis. While the 
studies in separate medical or surgical ICUs showed no significant difference in long 
term (90 day or 180 day) mortality between the intensive and conventional groups, the 
intensive group had an increased risk of long term mortality compared with control in 
studies with mixed ICUs (RR = 1.10, 95% CI: 1.02-1.19, p=0.01). Additionally, the 
intensive control group had significantly increased risk of hypoglycemia (characterized as 
blood glucose <40 mg/dL) compared with the conventional group (RR=5.01, 95% CI: 
3.45-7.28, p<0.00001). While these studies appear to conflict with the original Van den 
Berghe study, it should be noted that the original study compared this IIT with a blood 
glucose goal of 80-110mg/dL to the blood glucose standard of 180-200mg/dL. The 
majority of the subsequent studies compared IIT to a more moderate blood glucose (often 
<180mg/dL and most frequently in the 140-180mg/dL range19). Therefore, the mortality 
benefit in the original study may have been driven by avoiding excessive hyperglycemia 
during critical illness while subsequent studies showed that the approach may not need to 
be so ‘intensive’ to reap a benefit and additionally suggested the importance of avoiding 
severe hypoglycemia, which has its own consequences. 
Given this, current guidelines from the American College of Physicians 
recommend not using IIT to strictly control (80-110mg/dL) blood glucose in 
SICU/MICU patients with and without diabetes mellitus21. Based on their extensive 
literature review through January 2011, many of the trials showed no effect on mortality 
and there was no trend toward overall benefit to this strict approach. Rather, IIT was 
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associated with excess risk for hypoglycemia in almost all trials. Current 
recommendations suggest a target blood glucose level of 7.8 to 11.1 mmol/L (140 to 
200mg/dL) if insulin therapy is to be used in SICU/MICU patients.  
As the discussion above shows, much of the focus to date regarding 
hyperglycemia management has been related to defining the appropriate target population 
as well as target blood glucose range utilizing insulin therapy. Very little work has been 
put forth examining non-insulin mechanisms to prevent hyperglycemia or ameliorate 
insulin resistance. As discussed in the prior section, immobilization during ICU stay can 
exacerbate hyperglycemia and in turn early and aggressive ICU mobilization may be an 
untapped adjunctive and holistic intervention to better manage hyperglycemia. Another 
area of inquiry relevant in that vein, pertains to EN in the ICU.  
Review of Empirical Studies Regarding Enteral Nutrition  
Glucose excursion is a known response to provision of EN. However, 
administration of continuous EN during illness, may cause unwanted and exaggerated 
hyperglycemia. For example in the prospective observational study by Pancorbo-Hildalgo 
and colleagues, 64 internal medicine patients fed by nasogastric (NG) tubes at a hospital 
in Spain were examined. Over one third of the patients were found to have 
hyperglycemia as a complication22. While EN has been shown to be the preferred method 
of artificial nutrition over PN, there has been little rigorous investigation to date defining 
how best to provide EN—for example, as intermittent bolus feeds versus continuous (24 
hours a day). Currently, EN by continuous feeds are the status quo23.  
Few studies have explored how continuous versus intermittent feeds affects 
glucose. The limited that exist have been poorly designed with indistinct results and a 
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small sample size. In the study by Murphy et al., three different enteral feeding and 
insulin regimens were compared in a single hospital in the United Kingdom with the aim 
of improving glucose control and reducing hypoglycemia24. Part of the study was done 
with a retrospective analysis of the hospital’s current standard management of enteral 
feeds in diabetic patients (n=18) which involved 20 hour feeds with 30:70 premixed 
insulin. The second and third cohorts were analyzed prospectively. The first 13 eligible 
patients admitted were enrolled in the intermittent feed group and were administered 
three bolus feeds (4 hours each) with a basal bolus insulin regimen consisting of short 
acting insulin at each feed and long acting insulin at night. The next 15 consecutive 
eligible patients admitted were enrolled in the continuous feed group that incorporated 24 
hour feeds with a long acting insulin analog 1-2 times per day. Results did not show a 
significant difference in overall glucose control or a difference in glucose variability 
between all three groups. No significant difference was found in glucose concentrations 
between the groups during feeds or fasting. It is hard to know whether there were 
sufficient differences in the intervention itself, for example between the 20 hour fed 
group versus the 24 hour fed group. The retrospective group receiving the current 
standard resulted in a high incidence of hypoglycemia and overall suboptimal glucose 
concentration. Of note, somewhat counterintuitively, there were significantly fewer 
episodes of hypoglycemia during the feeding period in the intermittent feed group 
(p=0.006). There was a high level of glucose variability across 24 hours in each group, 
but no significant difference in variability between groups. The design of this study is a 
significant limitation, as one third of the data were collected retrospectively while the rest 
was collected prospectively, limiting the ability to match all three groups. Given that this 
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study included only diabetic patients, it is not generalizable to non-diabetics. The study 
size was quite small, and likely without sufficient power to detect a difference. 
Additionally, the small study size did not allow for control for potential confounders 
including severity of illness and concurrent infection. This was a small single center 
study and the majority of these patients had brain injury also leading to a lack of 
generalizability of the results. Several of the episodes of hypoglycemia (5 of 33 in the 
intermittent group, 2 of 24 in the continuous group, unable to be measured in standard as 
retrospective) were due to protocol violations which could be a concern for protocol 
adherence overall.  
Another comparative study by Campbell et al. looked at glucose control with 
continuous EN versus EN with feeding breaks25. This study included 20 ventilated 
patients in a seven bed combined medical and surgical ICU within a small district 
hospital. Enteral feeding was established after the third day of admission and data were 
collected for 48 hours. The control group received enteral feeding for 18 hours with 8 
hour breaks, and the intervention group received continuous enteral feeding over 24 
hours. The first 10 eligible patients were enrolled in the control group. Subsequent data 
collection was delayed a week allowing for adaptation of a new protocol before the next 
10 eligible patients were enrolled in the intervention group. Data were analyzed through a 
non-parametric Mann-Whitney approach, and results showed continuous enteral feeding 
reduced blood glucose levels significantly (p=0.005) as well as improved blood glucose 
control and reduced insulin requirements. This study has several limitations. The 
generalizability could be questioned given the small sample size in a small district 
hospital with a combined medical and surgical ICU. Data were only collected for 48 
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hours, and as critical illness and the associated stress hyperglycemia can fluctuate and 
persist for days, this may not have reflected the longer term effects of the intervention. 
This also could pose a problem in ensuring adequate time to meet nutritional goals that 
could affect blood glucose levels. Additionally, representation of medical and surgical 
patients between the groups was different; four surgical patients were in the continuous 
enteral feeding group versus one surgical patient in the intermittent feeding group. Blood 
glucose control could vary according to diagnosis as well as surgical intervention. It is 
important to note that the intermittent intervention of this study is not the physiologic 
three meal approach that we are proposing but rather just an 8 hour break from the 
continuous feeds. This is actually similar to the group in the Murphy trial discussed 
above which resulted in a high incidence of hypoglycemia and overall suboptimal 
glucose concentration24. 
 One additional study by Evans et al. was to determine if there was a difference in 
glycemic variability and insulin utilization in continuous tube feed (CTF) versus bolus 
tube feeds (BTF) in a prospective, randomized pilot study26. Secondarily, this study 
aimed to compare tube feed volume and caloric delivery as well as the incidence of 
hypoglycemia and the time needed to achieve >80% goal nutrition. From March 2012 to 
May 2014, in the surgical and neurological critical care units at a single institution, 50 
patients were enrolled and randomized to receive either BTF or CTF after percutaneous 
endoscopic gastrostomy (PEG) placement. Per protocol at this institution, all patients 
were placed on an insulin sliding scale regimen administered every 6 hours for treatment 
of blood glucose greater than 120. The study was designed to detect a mean difference of 
25% in primary endpoints (glycemic variability and insulin use) with power of 0.80 and 
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alpha <0.05. Results indicated that glycemic variability is not significantly affected by 
BTF versus CTF. The study also found that there was no significant difference in overall 
insulin utilization between the groups. No statistical differences were found in the 
secondary outcomes of median time to >80% goal nutrition, tube feed interruptions, and 
incidence of hypoglycemia as well. A strength of this study is its randomization, which 
the prior studies discussed have not achieved. While another strength of this study is that 
there were no statistically significant differences in age, gender, APACHE II, and body 
mass index (BMI) between control and intervention groups, a flaw is that given the 
relative small size of this study, additional potential important confounders could not be 
accounted for such as baseline presence of or control of diabetes mellitus as well as any 
corticosteroid use26. There was additionally a lack of strict inclusion/exclusion criteria 
based on diagnoses. Given its focus on PEG tube placement, the results lack external 
validity to patients with other enteral access methods (such as nasogastric or nasojejunal 
tube) or other healthcare settings. These studies by Murphy24, Campbell25, and Evans26 
are examples of the few studies examining intermittent versus continuous EN with 
inconsistent results and poor design. 
While human studies have been limited, the physiologic impact of continuous 
versus intermittent EN have been highlighted by animal studies. Stoll and colleagues 
utilized 60 female neonatal pigs who were fed by intermittent EN with polymeric 
formula, intermittent EN with elemental diet, EN continuously, or PN continuously for 
14 days27. Investigators administered IV glucose tolerance tests on days 7 and 14 and 
hyperinsulinemic euglycemic clamps on day 14 and found that in continuous EN and PN, 
insulin secretion during glucose tolerance test was significantly higher (p<0.05) and 
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glucose infusion rates during clamp were lower (p<0.05) than in the intermittent groups. 
These results indicate that that when nutrition (PN and EN) is given continuously there is 
a reduction in insulin sensitivity. Given that this study took place in animals, human 
studies are needed to further characterize these changes. 
The cyclic process of eating meals is a highly evolutionarily preserved process; it 
is not natural for our gastrointestinal (GI) tract or our endocrine system to receive 
nutrients continuously. Animal studies have shown that continuous nutrition induces GI 
tract atrophy as well as metabolic imbalance of key hormones that influence multiple 
organ systems28. Mechanistic human studies have shown that continuous nutrition also 
negatively affects intestinal hormones and consequent gallbladder function29,30. Apart 
from GI and endocrine studies, continuous nutrition also affects muscle synthesis, which 
in the ICU population is critically important as deconditioned and atrophied patients 
rehabilitate less well and portend a poorer prognosis31. Studies suggest that protein 
synthesis is less stimulated by continuous feeding versus intermittent feeding32. Finally, 
critical homeostatic mechanisms such as autophagy are interconnected with nutritional 
(fed-starved) cues and may impact recovery from critical illness33. Continuous feeding 
approaches may completely abrogate this response.  
While safety and tolerability is often cited to support continuous feeding as a 
gentler way to feed during illness, studies have shown that bolus feeds are tolerable. In 
the systematic review by Aguilera-Martinez et al.34, they aimed to examine the existing 
literature regarding the effectiveness of continuous EN versus intermittent EN. Inclusion 
criteria for the review required the studies to have patients over 18 year old with a NG 
tube receiving EN in the ICU. Ultimately six studies fulfilled the criteria including 
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randomized controlled trials, clinical trials without randomization, and before and after 
studies. Investigators defined continuous EN as gravity administered or by feeding pump 
continuously for 12 or more hours per day. Intermittent EN was defined as nutrition 
administered by bolus, gravity, or feeding pump several times per day with rest between 
feeds. No studies found a significant difference in digestive intolerance between groups. 
One study found that intermittent EN had a lower risk of aspiration pneumonia with an 
odds ratio = 0.146 (95% CI = 0.062-0.413; p = 0.000). Despite two studies showing 
better nutritional results in less time and possibly reduced aspiration pneumonia risk with 
intermittent EN, ultimately there was not sufficient evidence in these studies to support 
continuous versus intermittent EN methods. 
Given the lack of clear safety concerns and equipoise in terms of how optimally to 
provide nutritional support during critical illness, in the most recent 2016 guidelines, 
American Society for Parenteral and Enteral Nutrition (ASPEN) suggests intermittent 
bolus nutrition as one option23. As intermittent bolus feeds are tolerable, safe and could 
be considered more physiologic than continuous feeds, as well as may impact blood 
glucose excursions during illness by normalizing enterohormonal feedback loops, it is 
likely that this could be another untapped, adjunctive intervention for the treatment of 
hyperglycemia in the ICU.  
Review of Studies to Identify Possible Confounders  
 In this section, we will examine various confounding factors that may affect 
degree of hyperglycemia as well as the treatment but that will not be the primary focus of 
the proposed study. 
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Corticosteroids are well known to reduce insulin sensitivity in healthy 
individuals35. In the critical care setting, glucocorticoids are widely used as treatment for 
a range of inflammatory and allergic disorders36. There could be a concern that those 
critically ill patients treated with corticosteroids require higher insulin doses due to this 
insulin resistance. In order to control for this, the Evans study excluded patients that 
required corticosteroid use26. Given that this exclusion criteria eliminates a large amount 
of ICU patients, this is not ideal. The majority of the other relevant studies discussed 
have utilized a multivariate analysis to see if there are significant differences between 
groups. On univariate analysis, we will ensure that a relative equal proportion of patients 
in each group has steroid exposure during ICU stay.  
Another potential confounding variable is severity of disease. Do those who are 
sicker in the first place benefit from the intervention less than those who are healthier, or 
vice versa? One way that many studies have tried to acknowledge this confounder is a 
multivariate analysis adjusting for APACHE II scores6,17,19,25,37. The APACHE II score 
provides a summative score based upon initial values (the most deranged parameter 
within the first 24 hours of ICU illness) of 12 routine physiologic measurements, age, and 
previous health status to provide a measure of severity of disease (Appendix A)38. 
Combined with an accurate description of disease, this scale allows for the stratification 
by prognosis of acutely ill patients. Scores are from 0 to 71, and higher scores correlate 
with increased risk of hospital death. APACHE II is widely used and well validated 
among a heterogenous group of critically ill patients in the ICU and can be a useful tool 
to account for severity of illness in intervention studies.  
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Presenting diagnosis could also be considered a possible confounding variable. 
This is a common problem in ICU-related studies, particularly in the MICU where 
patients are heterogeneous. Several studies use a subgroup analysis by presenting 
diagnosis17. For example, the Campbell study comparing continuous versus bolus enteral 
feeding effects on blood glucose could be criticized for its that unequal representation of 
surgical and medical patients between the control and intervention25. While limiting a 
study to an exclusively medical or surgical ICU can help control for this confounder, this 
limits a study’s generalizability. Even the original Van den Berghe studies had slightly 
differing results in MICU39 versus SICU14.  
Analgesia and sedation are commonplace and often necessary in the ICU to 
provide comfort and safety to patients, especially those mechanically ventilated, but they 
can also lead to unexpected complications, prolonged mechanical ventilation, prolonged 
ICU LOS, and increased rates of delirium40. One proven way to combat this is an 
approach with an emphasis on awakening and breathing trials, choice of appropriate 
sedation, delirium monitoring, early mobility and exercise (ABCDE approach)41. Despite 
proven approaches such as this, some ICU patients are still found over-sedated (more 
than is clinically necessary) which ultimately becomes an obstacle to early mobilization. 
Some studies have tried to overcome this by controlling for degree of sedation using the 
Richmond Agitation-Sedation Scale (RASS). This validated scale has established 
reliability between different raters in different healthcare positions (Appendix B)42. It has 
an ability to detect changes in sedation status over consecutive days of ICU care, against 
constructs of level of consciousness and delirium, and correlated with the administered 
dose of sedative and analgesic medications.  
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A final confounding variable relates to the way in which blood glucose is being 
measured and reported. In a 2005 study, investigators performed a comparison of glucose 
meter analysis of capillary blood (finger stick), glucose meter analysis of arterial blood, 
and blood gas/chemistry analysis of arterial blood in 30 consecutive adult medical and 
surgical ICU patients. Results demonstrated significantly better clinical agreement with 
the central lab for arterial samples (69.9% with glucose meter analysis and 76.5% with 
blood gas/chemistry analysis) in comparison with the finger sticks (56.8%). With 
episodes of hypoglycemia, overall clinical agreement was <70% and finger stick was as 
low as 26.3%43. These differences led to disagreements over treatment dose and titration 
of insulin for hyperglycemia.  
Ultimately, randomization should aide to control for these confounders. With 
randomization, patients have equal chance to be assigned to intervention or control, thus 
minimizing differences among groups by theoretically distributing people with particular 
characteristics among groups.  
Review of Relevant Methodology  
In this section, we will review the methodology of prior studies relevant to the 
proposed study and justify our methodology.  
Study Design  
While there have been a significant number of randomized controlled trials 
examining the use of insulin for the treatment of hyperglycemia in the ICU14,16-18,44, there 
have been very few studies examining adjunctive therapies that focus on non-insulin 
based approaches. The most convincing data for the benefit of early mobilization in 
hyperglycemia is from a secondary analysis of a previous study that may not have been 
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appropriately powered to examine those benefits6. A randomized controlled trial is 
needed to explore its role in reducing the insulin requirements.  
Continuous versus intermittent bolus EN have been compared in a few studies 
with no conclusive outcome. While animal studies have indicated benefit of intermittent 
bolus feeds in reducing insulin resistance27, human studies are limited and a randomized 
controlled trial is necessary to observe this impact. Although they only looked at patients 
with PEG tubes, Evans et al. had a well-designed randomized controlled trial26.  
Randomized controlled trials help to prevent selection bias and decrease the 
probability of confounders. Given the benefits of a randomized controlled trial, the design 
of previous studies, and the current equipoise regarding our interventions, this proposed 
study will be a dual center randomized controlled trial using a 2 x 2 factorial design to 
take place over a two year period. 
Inclusion and Exclusion Criteria  
 Among the studies discussed in this chapter, inclusion and exclusion criteria has 
varied. A majority of the studies included mechanically ventilated ICU patients over the 
age of 184,7,26,45. Regarding mobilization, several studies required patients to have 
baseline functional independence prior to admission4,7. Several studies excluded patients 
with injuries that may preclude mobilization like unstable spine or pelvis injury as well as 
those patients for whom death appears imminent or unstable1,4,45. Burtin and colleagues 
had extensive exclusion criteria such as conditions impairing movement (open abdominal 
wounds, extreme obesity defined as a BMI >35, serious bedsore or venous ulcers), body 
length <1.5m, preexisting diagnosis causing neuromuscular weakness, acute stroke, status 
epilepticus, coagulation disorders (INR >1.5 or platelets <50,000/mm3), and intracranial 
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pressure >20mmHg1. Schweickert et al. excluded patients with active GI bleeds, and 
active myocardial infarction, or an unsecure airway, as well as patients with raised 
intracranial pressure7. Patients have been excluded who were unable to follow simple 
verbal commands in English45 or if there was a prior history of cognitive impairment4 or 
dementia45. The primary ICU providers were also typically given the option to exclude 
their patient if in their opinion, it was felt to be unsafe to mobilize the patient45. Some 
studies excluded the patient for clinical instability, but what qualifies as being too 
unstable varies. For example, in one study, instability was defined by mean arterial 
pressure <65 or >110mmHg, systolic blood pressure >200, heart rate <40 or >130 beats 
per minute, respiratory rate <5 or >40 breaths per minute, or pulse oximetry <88%7 
whereas in another study, instability was defined as fraction of inspired oxygen>55%, 
partial pressure of oxygen in the arterial blood <65, minute ventilation >150 mL/body 
weight, respiratory rate >30 breaths per minute, need for significant vasopressive 
support1. 
Regarding the nutritional component, Murphy et al. required patients to have 
normal GI function and to be receiving full nutritional needs by EN24. Campbell and 
colleagues excluded patients receiving medications by mouth requiring feed breaks 25. 
Evans et al. excluded patients with any contraindication to enteral feeding as well as 
pregnant patients or those with prisoner status26. Patients have been excluded from EN 
related studies for intestinal fistula, obstruction, necrosis, or peritonitis46.  
Typical exclusion for those included in studies for ICU related hyperglycemia 
included those who developed diabetic ketoacidosis or hyperosmolar state, which would 
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then necessitate a different protocolized approach for that hyperglycemic emergency 
state19. Per ASPEN guidelines, EN should be held for esophageal or gastric dysmotility23. 
Intervention 
 One of our goal interventions is aggressive and early mobilization such as that 
seen in the Schweickert study7 and that implemented at the three academic institutions in 
the Engel paper3. The paired and second distinct intervention is an intermittent bolus 
nutrition protocol similar to that in the Evans and Murphy studies, simulating three 
meals24,26. This approach is unique compared to prior studies that have simply instituted a 
feeding break intervention such as 18hours continuous feeds with an 8 hour break25.  
Primary and Secondary Outcome Measures  
Studies looking at insulin alone as the treatment for hyperglycemia have looked at 
various primary outcomes including death from any cause during intensive care14,16, 
death from any cause in the hospital39, and death from any cause within 90 days15,19. The 
Evans study used primary endpoints of glycemic variability (defined as the difference 
between maximum and minimum value) as well as insulin utilization26. Given that we are 
looking at therapy for hyperglycemia in the ICU that will be an adjunct to insulin, it is 
logical that we will examine a primary outcome similar to that measured in the Patel 
study—median total daily insulin dose normalized to weight (units/kg/day)6. 
We will also examine some of the secondary outcomes measured in the trials 
discussed throughout this chapter. Several studies looked at secondary outcomes of ICU 
LOS12,13,20,45, hospital LOS16,24,45, ICU mortality7,16,17,45, 90 day mortality4,17,19, delirium 
days7, ventilator free days7,45, as well as serious adverse effects (including falls, cardiac 
arrest, rapid or new onset atrial fibrillation, ventricular tachycardia, oxygen saturation 
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<80% for >3min, unplanned extubation, loss of invasively inserted line4,20,45). An 
important secondary outcome to be measured is hypoglycemia defined as <40 
mg/dL17,19,20. 
Sample Size 
 As this is a unique proposal for adjunct therapy of hyperglycemia in critically ill 
patients and there are no prior studies that we can utilize for a precise determination of 
our sample size, to estimate, we must extrapolate from studies that justify our rationale 
and primary hypothesis. For example, the Campbell study had a similar study population 
of critically ill patients as well as an outcome measure of insulin dose. Comparing 
continuous versus intermittent EN in 20 critically ill patients, their data demonstrated an 
effect size of 2.4mL/hour versus 3.2mL/hour with a standard deviation of about 1.7. 
Utilizing a sample size calculator with this data, a power of 80, α of 0.05, the goal sample 
size for each arm of the study was determined to be 71, leading to a total sample size of 
284. 
Conclusion  
 In this chapter, we have discussed numerous studies related to mobilization, 
treatment of stress hyperglycemia, and EN. Immobilization and EN have been shown to 
have a clear role in stress hyperglycemia in critically ill patients. Given controversy over 
the best treatment for this hyperglycemia, a study is needed to examine how EN and 
mobilization can be utilized in this area. Through our discussion of the methods of these 
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Chapter 3 – Study Methods 
Study Design 
This proposed study is a dual center randomized controlled trial designed to 
determine the effects of an early mobilization program and/or intermittent bolus EN upon 
glycemic control in the MICU utilizing a 2 by 2 factorial design.  
Study Population and Sampling 
 Eligible patients will be selected from two campuses within Yale New Haven 
Hospital. Adult patients aged 18 and greater who are admitted to the MICU at either York 
Street Campus (YSC) or Saint Raphael Campus (SRC) will be screened for eligibility. 
Yale New Haven Hospital is a 1500 bed tertiary care academic hospital. Patients who 
present to the emergency department at either campus can theoretically be admitted to the 
MICU at either location, dependent on bed availability. There are some caveats: where a 
bed is available at either campus, patients are kept at the campus where they present to 
minimize movement. Additionally, patients with certain disease processes are 
preferentially admitted to the YSC (such as patients undergoing liver transplant or 
patients with malignancy particularly if they are already cared for at the Smilow Cancer 
Center). Acuity of illness is otherwise similar.  
Inclusion criteria, as outlined in Table 2, will consist of mechanically ventilated 
males or females in the MICU over 18 years of age who are unable to ingest an oral diet 
but who have conserved GI function as well as baseline functional independence. 
Exclusion criteria, as detailed in Table 3, consists of those without enteral access, with a 
history of gastric bypass (or any surgery that may restrict stomach distension), with a 
history of significant esophageal dysmotility who would be at risk of aspiration, those 
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who cannot have their head elevated at least 30 degrees while intubated and being fed per 
standard protocol (such as those with elevated intracranial pressure), those chronically 
fed via a percutaneous gastric tube, those with a nasojejunal tube, those who are 
pregnant, those receiving infusions of neuromuscular blockade, and those with a 
hyperglycemic emergency (diabetic ketoacidosis or hyperglycemic hyperosmolar non-
ketotic coma) as well as any those with any contraindication to enteral diet such as 
intestinal fistula, obstruction, necrosis, peritonitis. Additional exclusion criteria are 
injuries that may require immobilization (such as unstable spine or pelvic fracture), 
increased intracranial pressure, active GI bleed, active myocardial infarction, cognitive 
impairment, dementia, or unable to follow simple English commands.  
Table 3.  Inclusion Criteria  
 
 
Table 4. Exclusion Criteria 
INCLUSION CRITERIA 
Over 18 years of age 
Admission to York Street Campus or St. Raphael’s Campus MICU 
Mechanical Ventilation 
Preserved GI function  
Baseline functional independence 
EXCLUSION CRITERIA   
Without enteral access   
History gastric bypass (or any other surgeries that may restrict stomach distension)  
History of esophageal dysmotility  
Unable to have head of bed elevated at least 30 degrees while intubated and being 
fed per standard protocol 
Chronically fed enterally via percutaneous gastric tube  
Nasojejunal tube  
Pregnant  
Receiving infusions or neuromuscular blockade 
Hyperglycemic emergency (diabetic ketoacidosis, hyperglycemic hyperosmolar 
non-ketotic coma)  
Injuries that preclude mobilization  
Increased intracranial pressure  
Active GI bleed  




Subject Protection and Confidentiality  
As either intervention is minimal risk with no significant alteration from current 
ICU practice that is offered as part of bundled supportive care for all patients, a waiver of 
informed consent will be obtained through the local institutional review board (IRB). We 
will collect data on all eligible patients.  
The study will be in compliance with HIPAA regulations, and patient 
confidentiality will be maintained throughout the study. Research data will be stored on a 
secure network. Per Yale research regulations, all participants will be de-identified, and 
identifiers and the means to link the names and codes will be stored in separate locations 
in the database per IRB protocol. A data and safety monitoring board will intermittently 
check the accruing data for benefits and harm and monitor for adverse events. This board 
will have the capability to terminate the study at any point if they have concerns about 
safety.  
Recruitment  
Consecutive patients who are admitted to the MICU who meet inclusion criteria 
will be included for analysis. This might include patients who are economically 
disadvantaged, decisionally impaired, employees or students who are admitted to the 
MICU, as well as women of reproductive age. There will be no exclusions made on the 
basis of gender, race, ethnic, economic or educational background. Vulnerable patients 
will not be specifically targeted or recruited for this study. Research staff will screen 
patients upon admission to the MICU on a daily basis. All patients will be included 
Cognitive impairment  
Dementia  
Unable to follow simple commands  
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consecutively once a determination is made by the primary treatment team to initiate 
nutritional support (typically within 24-48 hours of ICU admission as part of standard 
ICU supportive care) based on the usual clinical criteria. If an eligible patient is admitted 
and enrolled in the study, the ICU dietician will provide specific recommendations for 
continuous or intermittent bolus feeding dependent on randomization. The team will be 
notified of patient inclusion and will have an opportunity to decline participation if they 
feel there are unique factors that make the patient less suitable. Enrollment will be 
continuous until the goal patient enrollment number is met.   
MICU nursing staff, pharmacists, and providers will be notified of this study 
initiative prior to the start date and will be provided information about the relevant 
background and will be given a detailed standard operating procedure (SOP). The nursing 
staff will be intimately involved in the execution of the feeding intervention as they 
routinely administer EN in the ICU, and a frequently asked questions/SOP pamphlet will 
be provided (Appendix C). There will be ample opportunity to discuss concerns and 
questions. Nursing staff will be offered in-service sessions by the ICU dieticians and 
research team.  
Study Variables and Measures 
In the control arm, patients randomized will receive ad lib mobilization as ordered 
by the primary team and will be given continuous EN. In the intervention arm, patients 
will undergo rigorous early mobilization as well as a bolus EN protocol that simulates 
three meals and three snacks a day with no feeding period at night during sleep.  
The primary outcome of interest in this study will be degree of glycemic control 
defined by the number of insulin units (units/kg/day) required to treat hyperglycemia as 
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well as average blood glucose per hospital day. Additionally, this study will examine the 
secondary outcomes of ICU LOS, hospital LOS, ICU mortality, hospital mortality, 
delirium days, and other complications that may occur related to the intervention (such 
as, hypoglycemia, infection, aspiration, abdominal distension, number of patients who 
could not tolerate intermittent bolus meal and who were crosses over to continuous).  
Intervention  
With regard to the early mobilization intervention, state of the art early and 
aggressive PT/OT will be compared to ad lib PT/OT as ordered by primary team. At 
YSC, dedicated PT/OT staff has been secured specifically for the MICU for the last 
several years, allowing therapy 7 days a week with allocated resources to serve this 
population. Thus, patients admitted to the YSC will be automatically assigned to the 
aggressive mobilization intervention. At SRC, to date such resource arrangements have 
not yet been made, and PT/OT is ordered and administered ad lib according to resource 
availability.  
 For the nutrition intervention of the study, within 24 hours of admission to the 
MICU on either campus, patients will be randomly assigned to receive continuous enteral 
feeds or an intermittent bolus feeding protocol which will simulate three meals and three 
snacks a day. The actual timing of feeding initiation will be left to the discretion of the 
primary team. 
Blinding of intervention  
The allocation of patients for the two mobilization interventions depends on the 
hospital at which the patient is being treated. Thus, it will not be possible to blind the 
mobilization component of this study. For the nutrition intervention, treatment 
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assignments will be concealed before randomization, but due to the nature of the 
intervention, it will not be possible to blind care staff or patient. 
Adherence  
We will track PT/OT sessions in both groups to ensure that there is a sufficient 
difference between the arms of the study. The number of sessions a week, the number of 
minutes per session, the type of mobilization attempted, as well as patient progress will 
be followed. Both campuses utilize the electronic medical record system EPIC. In EPIC, 
templates will be created that will be filled out by the therapist after each session 
indicating the time and exercises performed with each patient. For the nutrition 
intervention, we will monitor calories per day, skipped meals or snacks as well as reason 
for being skipped (e.g. for a test, for intolerance, etc.), and number of hours fed per day 
for continuous infusion in a template form to be filled out by nursing staff.  
Data Collection 
Data will be continuously collected throughout the inpatient admission. Baseline 
data will be collected at the time of admission to allow for comparison of participant 
characteristics in each of the study groups. This data will include age, sex, BMI, baseline 
functional status, admitting diagnosis, APACHE II score, presence of sepsis, pre-existing 
diagnosis of diabetes mellitus, and use of concomitant therapies such as mechanical 
ventilation, renal replacement therapy, and corticosteroids.  
Blood glucose will be monitored and managed with insulin treatment according to 
the existing ICU hyperglycemia protocol (Appendix D). From the time of randomization 
to the time of discharge from the ICU or 90 days after randomization (whichever comes 
first) all blood glucose measurements, insulin administration, red cell administration, 
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positive blood cultures, volume of all EN, additional IV glucose administration, and 
corticosteroid administration will be recorded in EPIC. Aside from the timing of how EN 
and PT/OT will be administered, all other aspects of patient care will be carried out as 
appropriate by the treating physicians according to unit standards. Trial intervention with 
regard to nutrition will be discontinued once the patient is eating by mouth. For 
mobilization therapy, this will be continued until ICU discharge. Patients readmitted to 
the ICU during the same hospital encounter will be re-enrolled and assigned a different 
study number. Study participants will be followed until death or hospital discharge.  
Sample Size Calculation  
We will be using two-sided hypothesis testing with an alpha of 5%, a beta of 20% 
and a power of 80%. Using sample size calculator as discussed in Chapter 2, this leads to 
an unadjusted sample size of 71 patients in each arm, totaling 284 in the study. 
(Appendix E)  
Analysis 
The primary endpoint of median units of insulin used (units/kg/day) will be 
evaluated using a Kruskal-Wallis analysis. Kruskal-Wallis analysis will also be 
performed for the other continuous secondary outcomes (ICU LOS, hospital LOS, 
delirium days, ventilator free days). We will be using ANCOVA testing for further 
multivariate analysis controlling for potential confounding variables such as gender, race, 
age, severity of illness (APACHE II scores), organ failure scores, and caloric intake. The 




As we anticipate that these targeted interventions will be most beneficial for 
patients who remain in the ICU for greater than 3 days, a priori, the primary analysis of 
interest will focus on comparing the impact of the dual interventions between those in the 
ICU for greater than 3 days versus not. An intention to treat whole group analysis will 
also be performed as a secondary analysis. 
Timeline and Resources 
Patients will be continuously enrolled from September 2017 until June 2019 or 
sooner if a total of 284 patients are reached. Funding will be provided per the Yale 
School of Medicine. Staff will include co-principal investigators Caroline Argyros, PA-S 
and Shyoko Honiden, MD as well as a study coordinator and research assistants. This 
study will require the support of much of the MICU staff at both hospital campuses 
including medical providers, PT, OT, dieticians, and nurses.  
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Chapter 4 – Conclusion 
Strengths and Limitations 
This is a novel study investigating the efficacy of a non-insulin dependent 
multidimensional approach to the treatment of hyperglycemia among critically ill 
patients. The study focuses on supportive care already being provided in ICUs—EN and 
aggressive ICU mobilization. This holistic approach has the added benefit of minimizing 
severe hypoglycemia (blood glucose <40mg/dL) which has been the unavoidable ‘price’ 
paid in all prior studies which have investigated IIT. The randomized controlled trial 
design of this study allows demonstration of treatment effect more robustly than prior 
studies1,2. The strict inclusion and exclusion criteria should minimize risk to patients and 
help identify patients who are most likely to benefit (and be eligible) for our suggested 
approach in the real world. Additionally, as all outcomes will be measured while patients 
are in the hospital, no issues should occur with data collection, adherence, or loss to 
follow up. The study variables are well-defined and set data collection procedures are in 
place that should ideally prevent information bias. Another strength of this study is that 
the mobilization component utilizes a system already in place—comparing the 
differences in the aggressive early mobilization that should be occurring at YSC versus 
the ad lib mobilization occurring currently at SRC—making execution of the study 
practical in a reasonable timeframe. We hope that leveraging the existing realities in the 2 
study sites should also increase generalizability to a larger audience.  
 Despite the many advantages, there are a few notable limitations. It is a resource 
intensive study requiring the coordination of a multidisciplinary team which many prior 
studies have identified as difficult to implement3. Both of these protocols require 
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significant buy-in from staff which include dieticians, providers, nursing, as well as 
physical therapists. EN protocol is mostly nursing driven, and physical and occupational 
therapists are most integral to the mobilization component. Studies that take place in 
MICUs are classically plagued by the inherent heterogeneity of the patient population. 
Given that the mobilization arms are assigned based on which of the 2 study sites the 
patient is admitted to, it is possible that one site may see a larger proportion of certain 
diagnoses than others. However, we feel that the level of care provided is similar as 
providers go to both sites. Additionally ICU metrics and protocols used are the same 
between the sites minimizing bias. Severity of illness will be accounted for by the 
APACHE II score. Given the nature of both of these interventions, it is not possible for 
the clinician or patient to be blinded to the intervention or outcome. While administration 
of EN is a mostly patient independent process, mobilization requires patient participation 
and motivation. There could be an influence on outcome between patients who are more 
highly motivated or who have nurse or family members that encourage or allow for 
additional mobilization outside designated PT/OT sessions. It is important to be aware 
that early mobilization may in fact favor those patients that are destined to do well4 
especially when looking at the secondary outcomes of ICU and hospital mortality.  
While this study is limited in that it will not include any surgical or neurologic 
ICU patients, results of this study should be generalizable to most MICUs. Furthermore, 
the current study takes place at a large academic institution with significant resources. It 
may not be generalizable to smaller, more resource-limited hospitals—the biggest barrier 




Clinical Significance  
 Treatment of stress hyperglycemia in the critically ill patient has been a source of 
controversy for over a decade. To date, insulin has been the primary and sole treatment 
that has been extensively examined. Given the narrow therapeutic index of insulin1, 
finding the ideal target range for blood glucose has proven difficult. Given the 
implications of immobilization and EN on hyperglycemia, these would be ideal sources 
of intervention for a more physiologic and holistic approach to hyperglycemia versus a 
solely pharmacologic approach. Thus, this could lead to the incorporation of a bundled 
supportive care model utilizing EN and mobilization as treatment of hyperglycemia with 
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APPENDIX C: Sample Standard Operating Procedure: Intermittent Bolus Feeding 
 
A) Location: YSC or SRC MICU  
 
B) Eligibility: Patients over 18 years of age admitted to the MICU at YSC or SRC mechanically 
ventilated with preserved GI function who have an enteral feeding initiation order placed by the 
primary team. See Table 3 and 4 for full inclusion and exclusion criteria. 
 
C) Enrollment Process 
a) Research group to screen patients admitted to the MICU daily for inclusion/exclusion  
b) Waiver of consent obtained from IRB 
c) If eligible, treating team will be notified first (but can decide AGAINST intermittent feeding if 
special concerns as above) 
d) If an eligible patient is admitted, and decision to initiate enteral feeding is made by the primary 
team, the ICU nutritionist will confirm with research group re: inclusion/exclusion and if 
included, will provide recommendations for MEAL and SNACK volume versus 24 hour 
continuous feeding (current institutional default) 
e) There will be NO NEW enrollees on Saturday or Sunday (if already enrolled in study and 
receiving intermittent feeding this will continue over weekend as well) 
 
D) Nursing Guidelines 
 (1) Pour 24 hour total feeding volume as specified by Registered Dietician (RD) into 
enteral feeding bag 
 (2) Start with the next closest meal or snack time 
• Meal times: 6AM, NOON, 6PM  
• Snack times: 9AM, 3PM, 9PM 
(3) The RD note will specify what each meal or snack volume should be. Meals are 65-
75% of 24 hour volume, divided over 3 sessions. Snacks are 25-35% of 24 hour volume, 
divided over 3 sessions. The FIRST SNACK or MEAL given should be 50% of target 
volume. 
Example Case: RD prescription notes Pivot 1.3 cal/cc formula. Meal goal: 350cc each, 
Snack goal: 150cc each. It is now 2PM.  
Step 1: Pour 1500cc (350 x3 PLUS 150 x3; 24 hour total volume) into bag 
 Step 2: Plan on giving first snack at 3PM 
Step 3: Give as intermittent bolus feed using max rate of 400cc/hr (which is 6.5 
cc/min, equivalent to a little over a teaspoon every minute). First snack should be 
50% of target volume (which is 150cc for snacks). This means the patient will 
receive 75cc of feeds as a snack in approximately 11 minutes. 
Step 4: At 6PM the patient will be due for their first meal. First meal should be 
50% of target volume also (which in this case was 350cc). This means the patient 
will receive 175cc of feeds as a meal using max bolus feeding rate of 400cc/hr 
(6.5cc/min). Volume should infuse in about 25 minutes. 
 (4) If the first snack AND first meal given at 50% volume went well, for the next snack 
and meal titration up will continue. The volume will go up to 75% of target. 
Example Case:  
Step 5: If the preceding 3PM and 6PM feedings went well, for the next 
snack/meal you may titrate up to 75% of the goal volume. This would be for the 
9PM snack, and next meal 6AM breakfast meal. Bolus feeding rate will be the 
same as prior. 
(5) If the second snack AND first meal given at 75% volume went well, for the next 
snack and meal titration up will continue. The volume will go up to 100% of target. 
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Example Case:  
Step 5: If the preceding 9PM and 6AM feedings went well, for the next 
snack/meal you may titrate up to 100% of the goal volume. This would be for the 




 Volume Rate 
First Snack or Meal 50% target 400cc/hr 
First Snack or Meal (if started with snack, 
this would be meal or vice versa) 
50% target 400cc/hr 
Second Snack or Meal 75% target 400cc/hr 
Second Snack or Meal (if started with snack, 
this would be meal or vice versa) 
75% target 400cc/hr 
Third Snack or Meal  100% target 400cc/hr 
Third Snack or Meal (if started with snack, 
this would be meal or vice versa) 
100% target 400cc/hr 
 
What do I do if I encounter intolerance? What is enteral feeding intolerance? 
 Intolerance includes: abdominal pain, distension, vomiting, aspiration. Diarrhea can also 
be a sign of intolerance (although in the critically ill there may be other factors to consider as 
reasons for diarrhea). It is rarely severe enough to stop feeding. Please document instances of 
perceived enteral feeding intolerance. 
Gastric residual volumes (GRV) are no longer recommended to be routinely checked 
(SCCM/ASPEN updated nutrition guidelines for adult ICU patients from 2016). If still 
checking GRV due to institutional culture, only >500cc PAIRED with symptoms is 
considered significant (which is our current standard) 
 
(6) If there is concern for intolerance during a meal or snack at any point, may go back to 
the last tolerated volume and rate and slow down the titration (assure 2 successful 
sessions at those parameters before moving on) 
Similarly, if there is concern for refeeding syndrome titration could be similarly 
slowed down 
Example Case:  
Step 6: If the patient did not tolerate the 100% meal volume, you would go back 
to the last tolerated volume in which the patient reliably tolerated both a meal and 
snack (in this case 75% of target) and ensure 2 successful sessions (i.e. 2 snacks 
and 2 meals) at this volume before moving on.  If there is still signs of 
intolerance there can be consideration for adjuncts such as Reglan and/or 
erythromycin, and potentially modifiable risk factors that may be contributing to 
ileus (such as high dose narcotic infusion) should be discussed. The RN may call 
the resource number listed for the research team. 
Titration Table (Intolerance) 
 Volume Rate Observation Action 
First Snack  50% 
target 
400cc/hr tolerates  
First Meal  50% 
target 
400cc/hr tolerates  
Second Snack  75% 
target 
400cc/hr tolerates  
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Second Meal  75% 
target 
400cc/hr tolerates  
Third Snack  100% 
target 
400cc/hr tolerates  





DE-ESCALATE/SLOW DOWN  
Fourth Snack 75% 
target 
400cc/hr tolerates Go back to 
last tolerated 
% volume for 
BOTH snack 
and meal 
Fourth Meal 75% 
target 
400cc/hr tolerates  
Fifth Snack  75% 
target 
400cc/hr tolerates Make sure 
tolerates at 
this volume 
for 2 snacks 
and 2 meals 
Fifth Meal 75% 
target 
400cc/hr tolerates  
Sixth Snack 100% 
target 











Seventh Snack 100% 
target 







Seventh Meal 100% 
target 
400cc/hr tolerates  
Eighth Snack 100% 
target 
400cc/hr tolerates Stay at 100% 
Eighth Meal 100% 
target 
400cc/hr tolerates  
 
What do I do with my free water flushes that are separately ordered by the team? 
In general, the 24 hour flush infusion practice is being phased out. Per updated nursing 
guidelines, each medication is now being flushed separately, if given enterally with 30cc 
of flush volume. (i.e. 8 tablets = 240cc of flushes). This medication flush volume should 
be charted so that the team can account for flush volumes already being given. 
 
If the patient recently received a large flush volume (>250cc) for meds or for 
management of hypernatremia, there should be a 60 minute interval between that flush 
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volume and the next snack/meal. To accomplish this, the snack/meal time can be ‘moved’ 
by +/- 30 minutes, and an effort should be made to slightly push back or push forward the 
flush timings to create a 1 hour interval. 
Example Case:  
Step 7: If the patient received 300cc as free water flushes at 8:30AM, the next 
meal which would have been a ‘snack’ at 9AM can be shifted back to 9:30AM.  
Alternatively, if the flushes were anticipated to occur at 9AM, an effort should be 
made to deliver the flush volume at 8:30AM instead whenever possible, so that 
the ‘snack’ could be given around 9:30AM (to allow for the approximate one 
hour interval).  
 
What do I do if my patient is away for a test (or in a procedure) and missed a meal/snack? 
If there is an opportunity to catch up within 30 minutes of the SCHEDULED snack/meal 
time, this should be done. Otherwise, if it’s been more than 30 minutes, that snack/meal should be 
simply skipped, and the patient would be fed the next bolus scheduled bolus nutrition. 
 
Example Case:  
Step 8: The patient is due for a ‘lunch’ meal at noon, but is off the floor for an 
MRI. The patients returns at 2PM. The ‘lunch’ noon meal should simply be 
skipped at that point, and the patient should receive the next scheduled bolus 
nutrition at 3PM as a ‘snack’.  
If the patient returned to the floor at 12:30PM, a catch up ‘lunch’ could be 
given at that point. As with the adjustment for flushes above, meals/snacks can 
be moved up or down by 30 minutes from the scheduled time to accommodate 
work flow, testing etc. After the 12:30PM late lunch, feeding would proceed as 
planned (e.g. next would be 3PM snack). 
 
What do I do if my patient has uncontrolled hyperglycemia and needs to go on insulin drip? 
Example Case:  
Step 9: The patient had been reasonably well controlled on high dose sliding 
scale insulin but now with increasing insulin resistance due to illness and also 
started on steroids. The team makes a decision to start an insulin infusion 
protocol (not DKA/HHNK). The Yale insulin infusion protocol (IIP) notes 
“begin in any ICU patient with more than 2 BGs >180mg/dl who is not expected 
to rapidly normalize their glycemic status. Patients who are eating, transferring 
out of ICU imminently, or pre-terminal or being considered for CMO status are 
not generally a candidate for this IIP”. In this instance we would consider the 
‘bolus’ enteral feeding similar to a patient who is eating. While the insulin 
protocol allows for some exception to this rule to allow select patients who are 
‘eating’ to still be on insulin infusion protocol (item 9 in guideline reads: ‘in the 
rare patient who is eating, consider giving SQ aspart PC to ‘cover’ the meal. In 
this circumstance don’t increase infusion rate during the first 3 hours PC.”), for 
the purposes of this pilot feeding study, those who are increasingly 
hyperglycemic who need insulin infusion will then be transitioned over to 
continuous enteral feeding to avoid unpredictable fluctuations in BGs and 
complex insulin infusion titration.  
 
What do I do if have to hold feeds for certain medications? (Synthroid, Dilantin) 
Example Case:  
Step 10: Patients who require feeding holds due to a select set of medications 
like Synthroid or Dilantin will have the medication administration time manually 
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adjusted by the ICU pharmacist so that the snack/meal times can remain the 
same. For example the default medication administration time for Synthroid is 
currently at 6AM. This would coincide with the breakfast meal. The Synthroid 
dose might be moved to 8AM to ensure that the patient is not fed for the 1 hour 
before and 1 hour after medication administration. 
 
My patient is now extubated. S/he is not yet ready to eat on their own and feeding will 
continue. What do I do? 
Example Case:  
Step 11: If the patient is extubated, but is deemed NOT yet ready to eat on their 
own, provided they still have an enteral feeding tube (in the stomach, NOT 
jejunum) they can continue on their intermittent bolus feeding protocol. 
 
Who do I call with questions during nights or weekends? 
 In general, NEW patient recruitment will NOT occur over the weekend. Patients who 
were already enrolled during the weekday and started on intermittent bolus feeding will 
CONTINUE to be fed in that manner. If a question occurs over the weekend, members listed in 
the resource contact list can be tried.  
 For nights, a select group of night intensivist attendings have been in-serviced with 
regard to the pilot project in detail and can also be approached with questions for the nights they 
are on duty (listed in resource contact list pool). If a night time issue occurs on a night when one 
of these core night intensivists are NOT on duty (and a solution cannot be found after reviewing 
common questions/FAQs on the SOP), then the question should be reserved until the morning 
when the rest of the resource pool team can be contacted. 
My patient is long term trach’d but not usually on the ventilator and had been eating at 
home. Is s/he eligible? 
 Yes. If the patient was previously eating by mouth, then they are eligible for this study. If 
the patient has a chronic feeding tube and receives most (or all) of their nutrition via the tube, 
they will NOT be eligible for this study. This includes patients who eat minimally by mouth for 
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